Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

The German Thorotrast Study: Recent Results and Assessment of Risks

Gerhard van Kaick, Andreas Dalheimer, Sakiko Hornik, Alexander Kaul, Dagmar Liebermann, Hertha Lührs, Andreas Spiethoff, Kurt Wegener and H. Wesch
Radiation Research
Vol. 152, No. 6, Supplement: The International Workshop on the Health Effects of Thorotrast, Radium, Radon and Other Alpha-Emitters 1999 (Dec., 1999), pp. S64-S71
DOI: 10.2307/3580117
Stable URL: http://www.jstor.org/stable/3580117
Page Count: 8
  • Read Online (Free)
  • Download ($10.00)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
The German Thorotrast Study: Recent Results and Assessment of Risks
Preview not available

Abstract

The German Thorotrast study comprises 2,326 patients and 1,890 controls. Forty-eight Thorotrast patients and 239 controls are still alive and are invited for a follow-up examination every 2 years. In the deceased patients, the following neoplastic diseases with excess rates were registered (Thorotrast/controls): liver cancer (454/3); cancer of the bile ducts, including gallbladder (42/7); myeloid leukemia (40/7); myelodysplastic syndrome (30/4); plasmacytoma (10/2); non-Hodgkin's lymphoma (15/5); bone sarcoma (4/1); malignant peritoneal or pleural mesothelioma (9/0). Dose calculations are based on results of whole-body counting, X-ray films, and data obtained from the hospital records on the volume of Thorotrast injected. For liver cancer, the cumulative risk estimate was calculated to be 40 per 104 person Sv (radiation weighting factor = 20). These figures are close to the results of the Danish study and are comparable to the results of the Life Span Study of A-bomb survivors after 40 years at risk with 18 to 48 liver cancers per 104 person Sv. For hematopoietic malignancies, the cumulative risk was calculated to be about 7 per 104 person Sv (radiation weighting factor = 20). This risk estimate is lower by a factor of 10 compared to the results of the Life Span Study.

Page Thumbnails

  • Thumbnail: Page 
S64
    S64
  • Thumbnail: Page 
S65
    S65
  • Thumbnail: Page 
S66
    S66
  • Thumbnail: Page 
S67
    S67
  • Thumbnail: Page 
S68
    S68
  • Thumbnail: Page 
S69
    S69
  • Thumbnail: Page 
S70
    S70
  • Thumbnail: Page 
S71
    S71